Matches in Wikidata for { <http://www.wikidata.org/entity/Q91033404> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q91033404 description "article scientifique publié en 2018" @default.
- Q91033404 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q91033404 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91033404 description "scientific article published on 01 August 2018" @default.
- Q91033404 description "wetenschappelijk artikel" @default.
- Q91033404 description "наукова стаття, опублікована в серпні 2018" @default.
- Q91033404 name "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 name "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 type Item @default.
- Q91033404 label "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 label "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 prefLabel "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 prefLabel "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 P1433 Q91033404-E0E7BED6-72B2-4A29-8EF0-E1BDF00EE7C9 @default.
- Q91033404 P1476 Q91033404-F3D90583-9F64-43B4-B0F1-13A57B73E793 @default.
- Q91033404 P2093 Q91033404-0D9CE0F4-CF6F-40D1-9114-AA8E8CAED26C @default.
- Q91033404 P2093 Q91033404-29C748F0-95D6-42BA-8A51-A718E7301FBA @default.
- Q91033404 P2093 Q91033404-2A5C4D57-E596-4B39-BD28-884AEB81F783 @default.
- Q91033404 P2093 Q91033404-3C7A22CA-B26A-41DC-81AB-FD8088FCF95F @default.
- Q91033404 P2093 Q91033404-5F0A66AE-0928-4AC4-8DE1-CD7FDF626F72 @default.
- Q91033404 P2093 Q91033404-6DBBB204-475A-4060-BA01-EEB9DFAEC72E @default.
- Q91033404 P2093 Q91033404-87CAB16F-223B-42DF-9A0A-CD1E052867D6 @default.
- Q91033404 P2093 Q91033404-9AD72AFE-C93D-49FF-800D-61E22072A08A @default.
- Q91033404 P2093 Q91033404-A2F4FB27-E8EA-45A4-9D36-75B411D80E69 @default.
- Q91033404 P2093 Q91033404-D2929F66-1B81-43B5-8A35-C63412BEE3D7 @default.
- Q91033404 P2093 Q91033404-D5EECB5B-911E-45BA-9708-3FBC36C7A13B @default.
- Q91033404 P304 Q91033404-D736552B-183B-4C5E-AF71-78D70F22BF52 @default.
- Q91033404 P31 Q91033404-03447AFB-FD5F-42B2-94F8-4C820A8FAA21 @default.
- Q91033404 P356 Q91033404-92938B40-0467-4475-9CDE-6413D3B802BC @default.
- Q91033404 P433 Q91033404-F9C30A0F-D701-481A-B9FF-06965B1E61A2 @default.
- Q91033404 P478 Q91033404-0F05A121-CBB3-48CB-928E-EB519D899DE7 @default.
- Q91033404 P50 Q91033404-63C1D4C3-FEAF-4DDB-820C-D61168BF8F81 @default.
- Q91033404 P577 Q91033404-17ECDCCC-A2EF-45EA-8F89-72AA16A30245 @default.
- Q91033404 P698 Q91033404-BAFAD193-7E0F-4F9D-9E02-2B2F9F6E7B23 @default.
- Q91033404 P921 Q91033404-7FAA1831-B106-423B-869F-3E2878FC6B10 @default.
- Q91033404 P921 Q91033404-BBDB506C-976C-48F2-B575-1E1F5F879EA0 @default.
- Q91033404 P932 Q91033404-098FC25E-E433-4C21-AA79-B477A0D8C1FF @default.
- Q91033404 P356 CELLJ.2019.5370 @default.
- Q91033404 P698 30124008 @default.
- Q91033404 P1433 Q26842100 @default.
- Q91033404 P1476 "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial" @default.
- Q91033404 P2093 "Fatemeh Abbasi" @default.
- Q91033404 P2093 "Fatemeh Moeininia" @default.
- Q91033404 P2093 "Leila Arab" @default.
- Q91033404 P2093 "Leila Sanjari" @default.
- Q91033404 P2093 "Nasser Aghdami" @default.
- Q91033404 P2093 "Neda Jarooghi" @default.
- Q91033404 P2093 "Seyed Massood Nabavi" @default.
- Q91033404 P2093 "Seyedeh Esmat Hosseini" @default.
- Q91033404 P2093 "Soura Mardpour" @default.
- Q91033404 P2093 "Tina Bolurieh" @default.
- Q91033404 P2093 "Vajihe Azimyian" @default.
- Q91033404 P304 "592-598" @default.
- Q91033404 P31 Q13442814 @default.
- Q91033404 P356 "10.22074/CELLJ.2019.5370" @default.
- Q91033404 P433 "4" @default.
- Q91033404 P478 "20" @default.
- Q91033404 P50 Q55221767 @default.
- Q91033404 P577 "2018-08-01T00:00:00Z" @default.
- Q91033404 P698 "30124008" @default.
- Q91033404 P921 Q206901 @default.
- Q91033404 P921 Q5452194 @default.
- Q91033404 P932 "6099146" @default.